

cn+
A1
~~active agent is *Hypericum perforatum* or a methanol or ethanol extract of *Hypericum*,
and wherein~~
said health disorder is not depression or migraine headache.

C2
3. (Amended) The method of Claim 1, wherein the health disorder treatable with
T-type calcium channel blockers is chronic heart failure, congestive heart failure,
ischemic condition, arrhythmia, angina pectoris, hypertension, hypoinsulinemia,
hyperinsulinemia, diabetes mellitus, hyperaldosteronemia, epilepsy, brain aging, a
neurodegenerative disease or preterm labor.

Ad B2
REMARKS

Claims 1-22 are pending in this application. By this Amendment, Claims 18-21
have been withdrawn without prejudice and Claims 1 and 3 are amended without
prejudice to conform with the requirements of the First Office Action.

In the First Office Action, a request was made for an affirmation of the restriction
requirement and election of species made on 9/26/00 by Mr. King Wong on behalf of the
Applicant. Applicant hereby affirms its election of the invention of Group I, Claims 1-17
and 22, and its election of species for an extract from *Hypericum perforatum* for
examination with traverse. Applicant contends that it is not a significant burden upon
the Examiner to examine both Group I and II concurrently. Applicant, therefore,
requests that Examiner extend the examination to encompass the other species of the
claims of Group I.

Claims 1-17 and 22 were rejected in the First Office action under 35 U.S.C. 112,
second paragraph as indefinite. In particular, Claims 1-7 were rejected for allegedly
containing an improper Markush Group. Applicant respectfully submits that this